UPLOAD Filing
BridgeBio Oncology Therapeutics, Inc.
Date: Sept. 3, 2025 · CIK: 0001869105 · Accession: 0000000000-25-009499
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-289940
Letter
Re: BridgeBio Oncology Therapeutics, Inc. Registration Statement on Form S-1 Filed August 29, 2025 File No. 333-289940 Dear Eli Wallace:
September 3, 2025
Eli Wallace Chief Executive Officer BridgeBio Oncology Therapeutics, Inc. 256 E. Grand Avenue, Suite 104 South San Francisco, CA 94080
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Maggie L. Wong, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> September 3, 2025 Eli Wallace Chief Executive Officer BridgeBio Oncology Therapeutics, Inc. 256 E. Grand Avenue, Suite 104 South San Francisco, CA 94080 Re: BridgeBio Oncology Therapeutics, Inc. Registration Statement on Form S-1 Filed August 29, 2025 File No. 333-289940 Dear Eli Wallace: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Maggie L. Wong, Esq. </TEXT> </DOCUMENT>